<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891471</url>
  </required_header>
  <id_info>
    <org_study_id>70/2020/CECT2</org_study_id>
    <nct_id>NCT04891471</nct_id>
  </id_info>
  <brief_title>WHOle Brain Irradiation or STEreotactic Radiosurgery for Five or More Brain Metastases (WHOBI-STER)</brief_title>
  <acronym>WHOBI-STER</acronym>
  <official_title>WHOle Brain Irradiation and STEreotactic Radiosurgery for Five or More Brain Metastases (WHOBI-STER): a Prospective Comparative Study of Neurocognitive Outcomes, Level of Autonomy in Daily Activities and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mediterranean Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Messina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Palermo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mediterranean Institute of Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This work aims to evaluate neurocognitive performance, daily activity and quality of life and&#xD;
      local control among patients with brain metastasis (MBM) ≥ 5 due to solid tumors treated with&#xD;
      Stereotactic RadioSurgery (SRS) or Whole Brain RadioTherapy (WBRT). This multicentric&#xD;
      randomised controlled trial will be conducted at the Fondazione IOM (Viagrande) in&#xD;
      collaboration with REM (Viagrande), Hospital G. Martino (Messina) and Hospital Civico ARNAS&#xD;
      (Palermo). It will involve, within 5 years starting from 15 September 2020, the enrollment of&#xD;
      100 patients (50 for each arm) with MBM ≥ 5, age ≥ 18 years, Karnofsky Performance Status&#xD;
      (KPS) ≥ 70, life expectancy &gt; 3 months, histological confirmation of primary tumor, with&#xD;
      controlled or controllable extracranial disease, baseline Montreal Cognitive Assessment&#xD;
      (MoCA) of 20/30, Barthel Activities of Daily Living score 90/100, to be subjected to SRS on&#xD;
      each brain lesion by LINAC with monoisocentric technique and non-coplanar arcs (experimental&#xD;
      arm) or to WBRT (control arm). The primary endpoints are neurocognitive performance, quality&#xD;
      of life and autonomy in daily-life activities variations, the first one assessed by Moca&#xD;
      Score and Hopkins Verbal Learning Test - Revised, the second one through the European&#xD;
      Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15&#xD;
      Palliative Care (EORTC QLQ-C15-PAL) and Brain Neoplasm (BN-20) questionnaires, the third one&#xD;
      through the Barthel Index, respectively. The secondary endpoints are time to intracranial&#xD;
      failure, overall survival, retreatments frequency, acute and late toxicities, KPS decrease.&#xD;
      It will be considered significant a statistical difference of at least 29% between the two&#xD;
      arms (statistical power of 80% with a significance level of 95%). This trial has been&#xD;
      approved by the local ethics committee on July 7th 2020 (record 70). Several studies debate&#xD;
      what is the predominant factor accountable for the development of neurocognitive decay among&#xD;
      patients undergoing brain irradiation for MBM: radiotherapy, especially if extended to the&#xD;
      entire brain, or intracranial disease progression? Answer to this question may come from&#xD;
      current opportunity, thanks to recent technological advancement, to treat, with significant&#xD;
      time savings, improved patient comfort and at the same time minimizing the dose to healthy&#xD;
      brain tissue, Multiple Brain Metastasis simultaneously, otherwise attackable only by&#xD;
      panencephalic irradiation. The pursuit of a local control rate comparable to that obtainable&#xD;
      with WBRT remains the fundamental prerequisite for the aforementioned related assessments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive changes detected through Moca Score</measure>
    <time_frame>Change from Baseline pre-Radiotherapy Neurocognitive Functional Status every three months after treatment through study completion, an average of 1 year</time_frame>
    <description>To assess how neurocognitive performance changes after SRS/SBRT compared to WBI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Autonomy in daily activities detected through the Barthel Index</measure>
    <time_frame>Change from Baseline pre-Radiotherapy Barthel Index every three months after treatment through study completion, an average of 1 year</time_frame>
    <description>To assess how level of autonomy in activities of daily living changes after SRS/SBRT compared to WBI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life detected though the EORTC QLQ-C15-PAL questionnaire</measure>
    <time_frame>Change from Baseline pre-Radiotherapy EORTC QLQ-C15-PAL questionnaire every three months after treatment through study completion, an average of 1 year</time_frame>
    <description>To assess how quality of life changes after SRS/SBRT compared to WBI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurocognitive changes detected through Hopkins Verbal Learning Test - Revised</measure>
    <time_frame>Change from Baseline pre-Radiotherapy Neurocognitive Functional Status every three months after treatment through study completion, an average of 1 year</time_frame>
    <description>To assess how neurocognitive performance changes after SRS/SBRT compared to WBI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life detected though the BN-20 questionnaire</measure>
    <time_frame>Change from Baseline pre-Radiotherapy BN-20 questionnaire every three months after treatment through study completion, an average of 1 year</time_frame>
    <description>To assess how quality of life changes after SRS/SBRT compared to WBI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to local failure</measure>
    <time_frame>every three months after treatment through study completion, an average of 1 year</time_frame>
    <description>Time between treatment and cerebral disease progression detected through Magnetic Resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>after treatment completion through study completion, an average of 1 year</time_frame>
    <description>Time from the first day of treatment to exitus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-treatment rate</measure>
    <time_frame>after first treatment completion through study completion, an average of 1 year</time_frame>
    <description>Difference in needing further subsequent radiotherapy treatment between SRS/SBRT and WBI arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Central Nervous System (CNS) toxicities evaluated by means of Radiation Therapy Oncology Group (RTOG)/ European Organization for Research and Treatment of Cancer (EORTC) Radiation Toxicity Grading</measure>
    <time_frame>from treatment completion until three months later</time_frame>
    <description>Toxicities registered within three months from treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Central Nervous System (CNS) toxicities evaluated by means of Radiation Therapy Oncology Group (RTOG)/ European Organization for Research and Treatment of Cancer (EORTC) Radiation Toxicity Grading</measure>
    <time_frame>from three months after treatment completion through study completion, an average of 1 year</time_frame>
    <description>Toxicities registered after three months from treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky Performance Status changing</measure>
    <time_frame>after treatment completion through study completion, an average of 1 year</time_frame>
    <description>Evaluation of how patient's performance status modifies after treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neurocognitive Deficit</condition>
  <condition>Quality of Life</condition>
  <condition>Activities of Daily Living</condition>
  <arm_group>
    <arm_group_label>SRS/SBRT arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with five or more brain metastasis assigned by randomization to Stereotactic RadioSurgery (SRS) or Stereotactic Body RadioTherapy (SBRT) will be treated with a highly-conformal metastasis-directed single dose between 15 and 24 Gy or fractionated dose (e.g. 27 Gy in 3 fractions), respectively, depending on lesion size, while sparing clinically negative brain. The treatment will be delivered using five non-coplanar arcs and a mono-isocentric technique.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBI arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with five or more brain metastasis assigned by randomization to Whole Brain Irradiation (WBI) will be treated using a 3D-Conformal RadioTherapy technique for a uniform dose delivery of 30 Gy in 10 daily/fractions to the target, that is entire brain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic RadioTherapy</intervention_name>
    <description>To treat only brain metastasis identified through Magnetic Resonance imaging by means of stereotactic radiotherapy (experimental intervention) to determine if sparing of clinically uninvolved brain implies a better neurocognitive performance, quality of life and level of autonomy in activities of daily living respect to Whole Brain Irradiation (active comparator).</description>
    <arm_group_label>SRS/SBRT arm</arm_group_label>
    <other_name>Stereotactic RadioSurgery</other_name>
    <other_name>Stereotactic Body RadioTherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole Brain Irradiation</intervention_name>
    <description>To irradiate the entire brain, site of at least 5 parenchymal metastasis.</description>
    <arm_group_label>WBI arm</arm_group_label>
    <other_name>Whole Brain Radiotherapy, Panencephalic Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Brain metastases number ≥ 5&#xD;
&#xD;
          -  Primary tumor histologic diagnosis&#xD;
&#xD;
          -  Complete Extracranial staging&#xD;
&#xD;
          -  Montreal Cognitive Assessment ≥ 20/30&#xD;
&#xD;
          -  Barthel Activities of Daily Living ≥ 90/100&#xD;
&#xD;
          -  KPS ≥ 70&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Brain-MRI contraindications&#xD;
&#xD;
          -  Contraindications to SRS&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Hemorrhagic cerebral disease&#xD;
&#xD;
          -  Miliary metastases&#xD;
&#xD;
          -  Massive perilesional edema&#xD;
&#xD;
          -  Leptomeningeal involvement&#xD;
&#xD;
          -  Previous brain irradiation&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Non-solid brain tumor&#xD;
&#xD;
          -  Ischaemic event&#xD;
&#xD;
          -  Alcohol and/or drugs abuse&#xD;
&#xD;
          -  Anxiety and depression&#xD;
&#xD;
          -  KPS ≤ 60&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianluca Ferini</last_name>
    <role>Principal Investigator</role>
    <affiliation>REM Radiotherapy (parent company of Mediterranean Institute of Oncology)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gianluca Ferini</last_name>
    <phone>+393311341117</phone>
    <email>gianluca.ferini@grupposamed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione Istituto Oncologico del Mediterraneo</name>
      <address>
        <city>Viagrande</city>
        <state>Catania</state>
        <zip>95029</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene R. Cravagno, Chief Radiation Oncology Unit</last_name>
      <email>irene_rita.cravagno@fondazioneiom.it</email>
    </contact>
    <contact_backup>
      <last_name>Anna Viola, Radiation Oncologist</last_name>
      <email>anna.viola@fondazioneiom.it</email>
    </contact_backup>
    <investigator>
      <last_name>Anna Viola, Radiation Oncologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>REM Radiotherapy (parent company of Mediterranean Institute of Oncology)</name>
      <address>
        <city>Viagrande</city>
        <state>Catania</state>
        <zip>95029</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Ferini, Chief Radiation Oncology Unit</last_name>
      <phone>+393311341117</phone>
      <email>gianluca.ferini@grupposamed.com</email>
    </contact>
    <investigator>
      <last_name>Gianluca Ferini</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vito Valenti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonella Tripoli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Unit - Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvana Parisi</last_name>
      <phone>+393406284095</phone>
      <email>silvana.parisi@unime.it</email>
    </contact>
    <contact_backup>
      <last_name>Silvana Parisi</last_name>
      <email>silvana.parisi@unime.it</email>
    </contact_backup>
    <investigator>
      <last_name>Silvana Parisi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefano Pergolizzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Pontoriero</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alberto Cacciola</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Lillo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology, ARNAS-Civico Hospital</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Mortellaro</last_name>
      <phone>3298811698</phone>
      <email>gianlucamortellaro@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Ferrera</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple brain metastasis</keyword>
  <keyword>neurocognitive decay</keyword>
  <keyword>whole brain radiotherapy</keyword>
  <keyword>stereotactic radiosurgery</keyword>
  <keyword>stereotactic body radiotherapy</keyword>
  <keyword>quality of life</keyword>
  <keyword>solid tumor</keyword>
  <keyword>Activities of Daily Living</keyword>
  <keyword>best supportive care</keyword>
  <keyword>palliative radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

